Study on haemophilia care in Asia and Pacific
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at the experiences of people with haemophilia, their caregivers, and doctors in Asia and the Pacific. The goal is to understand current care and find ways to improve it. You may be asked about your treatment and daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with haemophilia A or B for at least 2 years.
- If you are under 18 (or 19 in South Korea), your parent or guardian must agree to join the study with you.
- You can speak English or the local language.
- You agree to sign a consent form explaining the study.
- For doctors: you are a haematologist with over 5 years of experience treating haemophilia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows young adults with severe hemophilia who joined the TRANSHEMO project as teenagers. It looks at how the transition to adulthood affects their health and daily life, and aims to improve care for others like them.
This study uses a survey to understand what matters most to people with haemophilia A when choosing treatments. Your answers could help doctors and researchers design better care options.
This study collects information from people with hemophilia about how treatments and daily life affect them. It uses your answers to improve patient-focused care and understand what challenges matter most.
This study looks at how prophylactic treatment for hemophilia affects your daily life, sleep, and feelings about your health. It compares different types of clotting factor concentrates to see if one is easier to manage than the other.
This study looks at the oral health and quality of life related to oral health in children with hemophilia. It aims to understand how hemophilia affects dental health and daily life.
This study is for adults in South Korea with acquired hemophilia A, a rare bleeding disorder. It tests a drug called Obizur to see how well it works for people who need it to control bleeding.
Hear when a new Haemophilia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.